India Inspects 90% of Cough Syrup Makers, Finds Compliance Lapses Amid Safety Concerns

India's drug regulator has inspected about 90 percent of the country's cough syrup manufacturers, uncovering compliance lapses including breaches of good manufacturing practices and inadequate testing. These inspections follow incidents where contaminated syrups, notably Coldrif by Sresan Pharmaceutical, were linked to child deaths domestically and abroad. Authorities have issued corrective action notices and taken measures such as license cancellations and unit closures. The regulator aims to enhance oversight, align with international standards, and eliminate quality issues without specifying a timeline.